ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 246

Routine Assessment of Patient Index Data 3 (RAPID3) Is a Valid Index for Routine Care in Patients with Osteoarthritis

Alfredomaria Lurati1, Luca Bertani1, Daniela Bompane1, Mariagrazia Marrazza1, Katia Angela Re1 and Magda Scarpellini2, 1Ospedale Fornaroli, Rheumatology Unit, Magenta, Italy, 2Rheumatology Unit, Ospedale Fornaroli, Magenta, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: RAPID3 (routine assessment of patient index data) is an arithmetic composite index of three Core Data Set, patient self-report, measures: physical function (0-3 converted to 0-10), pain (0-10), and patient global estimate (0-10) for a total of 0-30. It can be completed in the waiting room and can be calculated in only few seconds. Aim of this study was to compare RAPID3 with the Western Ontario and Mc-Master Universities Osteoarthritis Index (WOMAC) in patients with knee or hip osteoarthritis (OA)

Methods: patients with symptomatic knee or hip osteoarthritis as main rheumatologic diagnosis (VAS pain > 50 on a visual scale 0-100mm) according to the ACR (American College of Rheumatology) criteria and with stage 2 or 3 according to the Kellgren-Lawrence radiographic criteria were eligible. All subjects were clinically evaluated individually by an experienced rheumatologist and were asked to complete the self-report questionnaires (the original version of the WOMAC for hip or knee osteoarthritis and the RAPID3). There was no specific order in which the tests were completed; rather, each participant selected the order. Agreement between WOMAC and RAPID3 scores was estimated with rho Spearman correlation statistic and Cohen’s kappa.

Results: 478 patients (155 males, 323 females) with hip (n=38) or knee (n=70) osteoarthritis were enrolled in daily practice clinical care during 2010-2012. Mean age (±SD) was 63±14.4 years old.  Mean score was 67±9.1 for WOMAC and 6.5±2.1 for RAPID3. RAPID3 and WOMAC have shown a global correlation rho index of 0.72 (p<0.01) and a Cohen’s kappa of 0.7. Computing analysis for diagnosis, the means of WOMAC and RAPID3 weren’t significantly different between patients with hip or knee osteoarthritis (67± 9.9 vs 68±6.8 and 6.4±2.1 vs 6.6±2.1, respectively. p>0.05). The Spearman’s rho was 0.63 for hip osteoarthritis (p<0.01) and 0.78 for knee osteoarthritis. Cohen’s kappa was 0.68 for hip osteoarthritis (p< 0.01) and 0.78 for knee osteoarthritis, respectively.

Conclusion: Up to date there’s not literature about the use of RAPID3 in patients with OA. In our study we found a strong correlation between RAPID3 and WOMAC in patients with either hip and knee OA, confirmed by a linear regression model developed using all variables collected. RAPID3 provide informative quantitative data for patient status from one visit to the next comparable to other self-reported questionnaire as WOMAC in a time sparing manner.


Disclosure:

A. Lurati,
None;

L. Bertani,
None;

D. Bompane,
None;

M. Marrazza,
None;

K. A. Re,
None;

M. Scarpellini,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/routine-assessment-of-patient-index-data-3-rapid3-is-a-valid-index-for-routine-care-in-patients-with-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology